大阪大学 · 医学
Kei Kamide教授の研究室は、心血管疾患や代謝疾患の発症に関与する非コーディングRNA、特にANRILの機能解明を柱としています。特に染色体9p21領域に位置するANRILが腫瘍 suppressor遺伝子のエピジェネティックな制御を通じて細胞増殖や加齢性変化に与える影響を解明しており、疾患の発症メカニズムの解明を目指しています。また、RGS2遺伝子の多形性やレニン-アンジオテンシン系・シンパシック神経系の局在的活性が心筋肥大に与える影響についても、動物モデルを用いた機能解析を進めています。
Figures are computed from collected data and may differ slightly.
ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. ANRIL has been shown to regulate its neighbor tumor suppressors CDKN2A/B by epigenetic mechanisms and thereby regulate cell proliferation and senescence. However, the clear role of
Our results suggest that genetic variations in RGS2 contribute partly to the hypertensive phenotype.
Left ventricular hypertrophy in FFR may be less dependent on systemic elevations of BP and more dependent on the RAS and the sympathetic nervous system. Use of an AT1 receptor antagonist might be the most beneficial way to prevent progression of LVH through direct effects on tissue RAS and the sympathetic nervous system in FFR. As these changes occur in a rat model with hyperinsulinemia, insulin may have a role in promoting LVH by activating the local RAS and sympathetic nervous system activity.
Open papers in the app to read, cite, and organize with AI.
